granulocyte-macrophage colony stimulating factor (GM-CSF)

BIOLOGICAL2 trials

Sponsors

National Cancer Institute (NCI), Lynn E. Spitler, MD

Conditions

Burkitt LymphomaLymphoma, Large-Cell, DiffuseLymphoma, Small Noncleaved-CellMalignant Melanoma, Metastatic

Phase 2

Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas

CompletedNCT00001237

National Cancer Institute (NCI)Burkitt Lymphoma, Lymphoma, Large-Cell, Diffuse, Lymphoma, Small Noncleaved-Cell

Start: 1989-03-31End: 2000-04-30Target: 120Updated: 2008-03-04

Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma

CompletedNCT01363206

Lynn E. Spitler, MDMalignant Melanoma, Metastatic

Start: 2011-05-31End: 2015-05-31Updated: 2020-03-19

Related Papers

Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies

Journal for ImmunoTherapy of Cancer2020-05-0111 citations